Post-transplant lymphoproliferative disorder in view of the new WHO classification: A more rational approach to a protean disease?

Nephrology Dialysis Transplantation

Volumn 25, Issue 7, 2010, Pages 2089-2098

  Mucha, Krzysztof ^a,b   Foroncewicz, Bartosz ^a,b   Ziarkiewicz Wróblewska, Bogna ^a   Krawczyk, Marek ^a   Lerut, Jan ^c   Pczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

EBV; histopathology; PTLD; SOT; transplantation

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EVEROLIMUS; FLUORODEOXYGLUCOSE; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; B CELL HODGKIN LIKE LYMPHOMA; BURKITT LYMPHOMA; CELL THERAPY; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEVER; FOLLICULAR LYMPHOMA; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HEPATITIS C; HEPATOSPLENIC T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; KIDNEY TRANSPLANTATION; LARGE CELL LYMPHOMA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CANCER; NK T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; WORLD HEALTH ORGANIZATION; ALGORITHM; CLASSIFICATION; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION;

ALGORITHMS; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 77954344943     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq231     Document Type: Review

References (80)

1. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587
2. Nalesnik MA. The diverse pathology of post-transplant lymphoproli-ferative disorders: the importance of a standardized approach. Transpl Infect Dis 2001; 3: 88-96
3. Tanner JE, Alfieri C. The Epstein-Barr virus and posttransplant lym-phoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60-69
4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2003; 4: 222-230
5. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516
6. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004; 40: 728-735
7. Jain A, Nalesnik M, Reyes J et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002; 236: 429-436
8. Opelz G, Naujokat C, Daniel V et al. Disassociation between risk of graft loss and risk of non-hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227-1233
9. Caillard S, Lelong C, Pessione F et al. Post-transplant lymphoproli-ferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735-2742
10. Guppy AE, Rawlings E, Madrigal JA et al. A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007; 84: 1534-1539
11. Wiesner RH. A long-term comparison of tacrolimus (FK 506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66: 493-499
12. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008; 13: 563-568
13. Kirk AD, Cherikh WS, Ring M et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619-2625
14. Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869-875
15. Marshall WL, Yim C, Gustafson E et al. Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J Virol 1999; 73: 5181-5185
16. Caillard S, Agodoa LY, Bohen EM et al. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006; 81: 888-895
17. Mañez R, Breinig MC, Linden P et al. Posttransplant lymphoproli-ferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462-1467
18. McLaughlin K, Wajstaub S, Marotta P et al. Increased risk for post-transplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570-574
19. Tsao L, His ED. The clinicopathologic spectrum of posttransplanta-tion lymphoproliferative disorders. Arch Pathol Lab Med 2007; 131: 1209-1218
20. Bakker NA, van Imhoff GW, Verchuuren EA et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80: 595-599
21. Opelz G, Döhler B. Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010; 89: 567-572
22. Kroes AC, van der Pijl JW, van Tol MJ et al. Rapid occurrence of lymphoproliferative disease after pancreas-kidney transplantation performed during acute primary Epstein-Barr virus infection. Clin Infect Dis 1997; 24: 339-343
23. Bakker NA, van Imhoff GW, Verchuuren EA et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327-334
24. Stevens SJ, Verschuuren EA, Verkuujlen SA et al. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma 2007; 43: 831-840
25. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-814
26. Smets F, Latinne D, Bazin H et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603-1610
27. Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008; 8: 1016-1024
28. Lee TC, Savoldo B, Barshes NR et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006; 20: 389-393
29. McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer 2009; 101: 1019-1027
30. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158: 4045-4051
31. Swerdlow SH, Webber SA, Chadburn A et al. Post-transplant lymphoproliferative disorders. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008
32. Katz BZ, Pahl E, Crawford SE et al. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transplant 2007; 11: 58-65
33. Webber SA, Naftel DC, Fricker FJ et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006; 367: 233-239
34. Hsi ED. Hematopathology. Philadelphia: Churchill Livingstone, 2007
35. Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961-968
36. Bustillo M, Perez MC, Otero GlzA et al. High grade lymphoma in a post-renal transplant patient. Description of a case and literature review. Nephron 2000; 84: 189-191
37. Ziarkiewicz-Wróblewska B, Górnicka B, Suleiman Wet al. Posttrans-plant lymphoproliferative disorder: morphological picture and diagnostic difficulties. Transplant Proc 2006; 38: 168-172
38. Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am JSurg Pathol 2006; 30: 1604-1612
39. Baccarani U, Adani GL, Montanaro D et al. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 2006; 38: 1135-1137
40. Lohrisch CA, Nevill TJ, Barnett MJ et al. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt ?s lymphoma. Leuk Lymphoma 2000; 39: 195-201
41. Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565
42. Tcheng WY, Said J, Hall T et al. Post-transplant multiple myeloma in a pediatric renal transplant patient. Pediatr Blood Cancer 2006; 47: 218-223
43. Hanson MN, Morrison VA, Peterson BA et al. Posttransplant T-cell lymphoproliferative disorders\an aggressive, late complication of solid-organ transplantation. Blood 1996; 88: 3626-3633
44. Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol 2007; 127: 887-895
45. Mucha K, Foroncewicz B, Niemczyk K et al. Tonsil enlargement after liver transplantation in adults\reason enough for tonsillectomy? Two cases of tonsillar posttransplantation lymphoproliferative disease. Liver Transpl 2007; 13: 918-923
46. Ziarkiewicz-Wróblewska B, Górnicka B, Ołdakowska U et al. Plas-macytic hyperplasia\the early form of posttransplant lymphoproliferative disorder\with atypical morphology and clinical course in patient after liver transplantation: a case report. Transplant Proc 2003; 35: 2320-2322
47. Ziarkiewicz-Wróblewska B, Górnicka B, Gierej B et al. Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation\unusual case report and literature review. J Pol Pathol 2008; 59: 63-69
48. Pitman SD, Huang Q, Zuppan CW et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006; 30: 470-476
49. Schlieper G, Kurschat C, Donner A et al. Hodgkin disease-like post-transplantation lymphoproliferative disorder of donor origin in a renal allograft recipient. Am J Kidney Dis 2006; 47: e37-e41
50. Ranganathan S, Webber S, Ahuja S et al. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttrans-plant Hodgkin lymphoma? Pediatr Dev Pathol 2004; 7: 348-360
51. Gottschalk S, Heslop HE, Rooney CM. Adoptive immunotherapy for EBV-associated malignancies. Leuk Lymphoma 2005; 46: 1-10
52. Everly MJ, Bloom RD, Tsai DE et al. Posttransplant lymphoprolifera-tive disorder. Ann Pharmacother 2007; 41: 1850-1858
53. Frey NV, Tsai DE. The management of posttransplant lymphoproli-ferative disorder. Med Oncol 2007; 24: 125-136
54. Cesarman E, Chadburn A, Liu YF et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294-2302
55. Nelson BP, Nalesnik MA, Bahler DW et al. Epstein-Barr virus-negative posttransplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375-385
56. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoprolifera-tive disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-167
57. Merlo A, Turrini R, Dolcetti R et al. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 2008; 8: 1265-1294
58. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845
59. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191
60. Comoli P, MaccarioR,LocatelliFet al. TreatmentofEBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specificT cells. Am J Transplant 2005; 5: 1415-1422
61. Sherritt MA, Bharadwaj M, Burrows JM et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive im-munotherapy. Transplantation 2003; 75: 1556-1560
62. Haque T, Wilkie GM, Jones MM et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131
63. Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproli-ferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848-852
64. Funch DP, Walker AM, Schneider G et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900
65. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T cell lymphomas, unspecified (or not otherwise specified): a review. Hematol Oncol 2008; 26: 8-20
66. Foroncewicz B, Mucha K, Usiekniewicz J et al. Posttransplant lym-phoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery. Transplant Proc 2006; 38: 173-176
67. Choquet S, Trappe R, Leblond Vet al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation. Haematologica 2007; 92: 273-274
68. Garrett TJ, Chadburn A, Barr ML et al. Posttransplantation lympho-proliferative disorders treated with cyclophosphamide-doxorubicin- vincristine-prednisone chemotherapy. Cancer 1993; 72: 2782-2785
69. Taylor AL, Bowles KM, Callaghan CJ et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant post-transplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006; 82: 375-381
70. Lee JJ, Lam MS, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007; 41: 1648-1659
71. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006; 19: 259-269
72. Trappe R, Hinrichs C, Appel U et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009; 9: 2331-2337
73. Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906
74. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of ri-tuximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057
75. Blaes AH, Peterson BA, Barlett N et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation. Cancer 2005; 104: 1661-1667
76. Jain AB, Marcos A, Pokharma R et al. Rituximab (Chimeric anti-CD20 antibody) for posttransplant lymphoproliferaive disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005; 80: 1692-1698
77. Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11: 113-116
78. Evens AM, David KA, Helenowski I et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28: 1038-1046
79. Cullis B, D'Souza R, McCullagh Pet al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47: e67-e72
80. Pascual J. Post-transplant lymphoproliferative disorder\the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22: i27-i35 (Pubitemid 47073742)